Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2021-05-20 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
52-109F1R - Certification of refiled annual filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification filed by the CEO of Theralase Technologies Inc. regarding the refiled annual financial statements for the year ended December 31, 2020. It is a certification under National Instrument 52-109, specifically a Venture Issuer Basic Certificate, which attests to the review and fair presentation of the annual filings but does not include the actual financial statements or detailed financial data. The document is short (3309 characters) and primarily serves as an officer certification rather than the full annual report or financial statements. According to the Certification Rule, such certifications should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or Audit Report (AR).
2021-05-20 English
Audited annual financial statements (amended) - English.pdf
Annual Report Classification · 100% confidence The document is titled 'Audited Consolidated Financial Statements As at December 31, 2020 and 2019' for Theralase Technologies Inc. It includes management's responsibility statement, an independent auditor's report, and detailed consolidated financial statements including statements of financial position, operations, and cash flows. The auditor's report is comprehensive and includes an opinion on the financial statements, basis for opinion, and notes on going concern. The document contains actual financial data and analysis for the full fiscal year ending December 31, 2020, and comparative data for 2019. This matches the definition of an Annual Report (10-K) which covers the company's full financial performance for the year. The document is not a brief announcement or a certification letter, but a full audited financial report. Therefore, the correct classification is Annual Report (10-K). FY 2020
2021-05-20 English
Notice of the meeting and record date - English.pdf
Regulatory Filings
2021-05-17 English
News release - English.pdf
Regulatory Filings
2021-04-28 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).pdf
Regulatory Filings
2021-04-28 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings
2021-04-28 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.